New research led by Katie Wong and colleagues indicates that neither urine albumin-to-creatinine ratio (UACR) nor urine protein-to-creatinine ratio (UPCR) is superior for predicting kidney failure or death in patients with rare glomerular diseases. While clinical guidelines for diabetic kidney disease often prioritize UACR, this study of 4,156 patients found comparable predictive performance across all proteinuria measurements, including non-albumin proteinuria.
Predicting Kidney Failure: UACR vs. UPCR
Clinical practice has long debated the most accurate method for assessing proteinuria. According to research published by Katie Wong and her team, current guidelines for diabetic kidney disease and chronic kidney disease (CKD) favor UACR. However, the study highlights that clinical practice for rare glomerular diseases often relies on UPCR, creating a discrepancy in diagnostic standards.
To determine if this difference impacts patient outcomes, the research team analyzed a cohort of 4,156 patients receiving rapid assessment for kidney disease. They evaluated the performance of these metrics using Cox regression models to track the time to either kidney failure or death. The study found that at lower predicted UACR deciles, converting UPCR to UACR resulted in measurable underestimations of the patient’s actual UACR, yet this did not change the clinical predictive value.
The study utilized Schwarz Bayesian information criterion (SBC) and Akaike information criterion (AIC) to assess model fit. Researchers observed that these values remained remarkably similar across all proteinuria metrics, suggesting that the choice of test may be less critical than previously assumed for long-term prognosis.
Evaluating Diagnostic Performance in Rare Kidney Diseases
The investigators assessed the model’s accuracy using receiver operating characteristic curves and time-dependent area under the curve (AUC). Across all disease subgroups and models, the 5-year time-dependent AUCs exceeded 0.83. This high level of concordance suggests that both UACR and UPCR are robust indicators of risk, provided they are used consistently.
The analysis revealed no statistically significant differences in model performance when comparing UACR, UPCR, non-albumin proteinuria, or estimated UACR derived from UPCR. Within each UACR tertile, the statistical metrics for model fit remained consistent. For clinicians, this implies that the specific proteinuria measurement selected may not significantly alter the ability to forecast patient outcomes in rare kidney disease cohorts.
Future Trends in Proteinuria Monitoring
Frequently Asked Questions
- Is UACR better than UPCR for diagnosing kidney failure?
According to the study by Katie Wong and colleagues, there is no statistically significant difference in the predictive performance of UACR and UPCR for kidney failure or death in patients with rare kidney diseases. - Why do clinical guidelines often prefer UACR?
Guidelines for diabetic kidney disease and CKD often prioritize UACR. - Does the type of proteinuria measurement matter for rare diseases?
The research indicates that for rare glomerular diseases, both metrics provide comparable predictive value for long-term outcomes, meaning neither is definitively superior for this specific patient population.
Are you a healthcare provider or a patient navigating the complexities of kidney health? Subscribe to our newsletter for the latest updates on clinical research and diagnostic standards.
